Author: Editor

David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/189127/abstract

David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/189127/abstract

David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/189127/abstract

Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line  

Ross Camidge, MD, PhD on Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial. Read here:https://meetinglibrary.asco.org/record/186906/abstract  

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial. Read here: https://meetinglibrary.asco.org/record/186906/abstract

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial. Read here: https://meetinglibrary.asco.org/record/186906/abstract

Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer. Background/Key Findings: 301 people with cancer (breast cancer = 153, lung cancer = 100, colorectal cancer = 48) who were treated with chemotherapy in the past year and experienced at least one episode of myelosuppression completed an online survey to assess the impact of chemotherapy-induced myelosuppression. Nearly nine in ten (89%) survey participants reported that myelosuppression had a moderate or major impact on their lives (moderate life impact = 49%, major life impact = 40%). Fatigue…

Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer. Background/Key Findings:   301 people with cancer (breast cancer = 153, lung cancer = 100, colorectal cancer = 48) who were treated with chemotherapy in the past year and experienced at least one episode of myelosuppression completed an online survey to assess the impact of chemotherapy-induced myelosuppression. Nearly nine in ten (89%) survey participants reported that myelosuppression had a moderate or major impact on their lives (moderate life impact = 49%, major life impact = 40%).…

Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer. Background/Key Findings: 301 people with cancer (breast cancer = 153, lung cancer = 100, colorectal cancer = 48) who were treated with chemotherapy in the past year and experienced at least one episode of myelosuppression completed an online survey to assess the impact of chemotherapy-induced myelosuppression. Nearly nine in ten (89%) survey participants reported that myelosuppression had a moderate or major impact on their lives (moderate life impact = 49%, major life impact = 40%). Fatigue…

Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy presented at this year’s virtual ASCO. Read here: https://ascopubs.org/doi/full/10.1200/JCO.20.00593

Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy presented at this year’s virtual ASCO. Read here: https://ascopubs.org/doi/full/10.1200/JCO.20.00593

J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health care network with large scale genomic NGS testing of advanced cancers in a community setting. Read here: https://meetinglibrary.asco.org/record/190712/abstract

J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health care network with large scale genomic NGS testing of advanced cancers in a community setting. Read here: https://meetinglibrary.asco.org/record/190712/abstract

J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health care network with large scale genomic NGS testing of advanced cancers in a community setting. Read here: https://meetinglibrary.asco.org/record/190712/abstract

Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.

Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.

Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.

Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year’s virtual ASCO.

Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/184901/abstract

Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year’s virtual ASCO. Read here: https://meetinglibrary.asco.org/record/184901/abstract

Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder cancer.

Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder cancer.

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here: https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for

Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results. Read here: https://www.exactsciences.com/newsroom/new-oncotype-dx-data-asco2020  

Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results. Read here: https://www.exactsciences.com/newsroom/new-oncotype-dx-data-asco2020

Earn CME: https://www.naccme.com/program/20-hemcovid-4 In this webcast, Drs. Joseph R. Mikhael leads a roundtable discussion with Drs. Jessica K. Altman, Michael Angarone, Matthew R. Levine, and Mary-Beth Percival and patient advocate Yelak Biru about management challenges faced by healthcare practitioners as they manage patients with hematologic malignancies during the COVID-19 pandemic, with a focus on the patient experience. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-3 In this webcast, Drs. Joseph R. Mikhael and Nina Shah discuss challenges faced by US healthcare practitioners as they manage the treatment of patients with myeloma during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-2 In this webcast, Drs. Joseph R. Mikhael and John P. Leonard discuss challenges faced by US healthcare practitioners as they manage the treatment of patients with lymphoma during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/20-hemcovid-1 In this webcast, Drs. Joseph R. Mikhael, John P. Leonard, Nina Shan, and Michael J. Satlin discuss challenges faced by US healthcare practitioners as they manage the treatment of patients with hematologic malignancies during the COVID-19 pandemic. © 2020 Imedex, an HMP Company

Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results. Read here: https://www.exactsciences.com/newsroom/new-oncotype-dx-data-asco2020

Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research

Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research

Philadelphia, PA (June 8, 2020) –  Oncoceutics announced today a Brown University award of $3.4 million that will be used to support a group of research teams for preclinical research, IND-enabling studies and a first-in-human clinical trial for Oncoceutics’ imipridone ONC212. As part of this award, Oncoceutics has received a $1M subaward to complete the IND-enabling studies for ONC212. ONC212 will be the third imipridone to enter clinical trials for oncology and is an agonist for the G protein-coupled receptor (GPCR) GPR132 and the mitochondrial protease ClpP, both novel targets that are highly expressed in cancer cells.The award goes to…

Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the BCMA CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma. Read here: https://meetinglibrary.asco.org/record/186155/abstract

Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma. Read here: https://meetinglibrary.asco.org/record/186155/abstract

Nicholas Vogelzang, MD of Comprehensive Cancer Center @CCCNevada discusses the single arm, phase 2, TRITON2 clinical trial supported FDA approval of Rubraca in mCRPC

Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO.

Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO.

Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose escalation and expansion of SGN-LIV1A administered weekly in breast cancer.

Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose escalation and expansion of SGN-LIV1A administered weekly in breast cancer.

Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed glioblastoma patients are alive12 months following treatment. Read here: http://s23.q4cdn.com/479936946/files/doc_news/INOVIOs-INO-5401-in-Combination-with-PD-1-Inhibitor-Libtayo-cemiplimab-Demonstrates-85-of-Newly-Diagnosed-Glioblastoma-Patients-Are-A-5VT78.pdf

Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed glioblastoma patients are alive12 months following treatment. Read here: http://s23.q4cdn.com/479936946/files/doc_news/INOVIOs-INO-5401-in-Combination-with-PD-1-Inhibitor-Libtayo-cemiplimab-Demonstrates-85-of-Newly-Diagnosed-Glioblastoma-Patients-Are-A-5VT78.pdf